Interleukin-6 promoter polymorphism: risk and pathology of Alzheimer's disease

P Y Zhang, AJ Hayes, A Pritchard, U Thaker, MS Haque, H Lemmon, R J Harris, A Cumming, JC Lambert, MC Chartier-Harlin, D St Clair, T Iwatsubo, DM Mann, Corinne L. Lendon

Research output: Contribution to journalArticlepeer-review

36 Citations (Scopus)


Inflammatory and immune responses are involved in the pathogenesis of Alzheimer's disease (AD). Interleukin-6 (IL-6), an inflammatory cytokine, is thought to play a role in neurodegeneration of the central nervous system and has been associated with increased amyloid precursor protein expression in vitro and greater cognitive decline. Previously a C−174G polymorphism in the promoter of IL-6, which influences expression in vitro, has been found associated in some studies but not all. We investigated this polymorphism in a large independent UK sample of AD cases (n=356) and controls (n=434) but found no association. We extended the study to genotype/phenotype correlations but found no correlation with age of onset (n=338), brain amyloid load (n=126) or Tau load (n=101), brain microglial cell load (n=65) or brain reactive astrocytes (n=127). Our data do not support a pathogenic role in AD for the C−174G polymorphism in isolation.
Original languageEnglish
Pages (from-to)99-102
Number of pages4
JournalNeuroscience Letters
Issue number2
Publication statusPublished - 20 May 2004


  • Alzheimer's disease
  • polymorphism
  • interleukin-6
  • promoter
  • brain
  • amyloid load
  • microglial cell load
  • reactive astrocytes


Dive into the research topics of 'Interleukin-6 promoter polymorphism: risk and pathology of Alzheimer's disease'. Together they form a unique fingerprint.

Cite this